Targeting therapy is a concept that has gained significant importance in recent years,
especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate …

Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been
successfully used for diagnosis and therapy of prostate cancer. Optimization of the available …

In the past two decades, extensive efforts have been made to develop agents targeting
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …

Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional
chemotherapy has wide variety of disadvantages such as high systemic toxicity and low …

Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II
(GCPII), has recently emerged as a prominent biomarker of prostate cancer (PC) and as an …

Prostate cancer is the most prevalent male malignancy in the United States, and remains the
second leading cause of cancer-related death in the male population. Prostate specific …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …

Background/Aim: Prostate-specific membrane antigen (PSMA) is emerging as a target for
treatment of castration-resistant prostate cancer (CRPC) while its up-regulated in the …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

In an effort to seek novel agents targeting prostate-specific membrane antigen (PSMA), 16
ligands (L1–L16) with structural modifications in S1′ binding pocket were synthesized and …